STOCK TITAN

Bio-Techne Corp - TECH STOCK NEWS

Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.

Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.

This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.

All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.

News
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced a dividend of $0.08 per share for the quarter ended December 31, 2023. The quarterly dividend will be payable on February 26, 2024, to all common shareholders of record on February 12, 2024. Bio-Techne is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities, generating approximately $1.1 billion in net sales in fiscal 2023 with approximately 3,200 employees worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
dividends
-
Rhea-AI Summary
Bio-Techne's Advanced Cell Diagnostics (ACD) achieves a technical breakthrough with the development of a protease-free RNAscope spatial multiomics workflow, enabling same-slide detection of protein and RNA biomarkers with unparalleled sensitivity and tissue morphology. The new innovation allows for simultaneous imaging of both RNA and protein biomarkers on the same tissue section, providing an unprecedented single-cell view of disease pathology and therapeutic response. The advanced workflow preserves protein and RNA integrity, simplifies image and data analysis, and will be showcased at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced the launch of the first fully automated spatial multiomics workflow, revolutionizing predictive biomarker research and drug development. The solution integrates RNA and protein data at the subcellular level in spatial tissue context without user intervention, offering high throughput and reliable target detection. The multiomics application will be commercially available in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
none
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) welcomed presentations from Pfizer and Sanofi at the WCBP conference, showcasing the transformative impact of MauriceFlex™ system on biotherapeutic development processes. MauriceFlex™ offers charge variant characterization and protein size analysis, addressing limitations in traditional methods. Presentations demonstrated its efficiency in AAV gene therapy development and collecting charge variants of complex proteins for downstream mass spectrometry characterization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) has announced a conference call and webcast to review its second-quarter fiscal 2024 financial results. The call is scheduled for February 1, 2024, at 8:00 a.m. CST. Bio-Techne is a leading developer and manufacturer of high-quality purified proteins, reagent solutions, and diagnostic products. The company generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
conferences earnings
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced the appointment of Matthew F. McManus as President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus brings over two decades of senior life sciences leadership experience and will succeed Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has a strong track record in the life sciences industry, having previously served as Executive Vice President and Chief Operating Officer for Azenta and as Senior Vice President and General Manager of Bio-Techne's Molecular Diagnostics Division. He also has a background in gene synthesis and cell & gene therapy markets. Kim Kelderman, Bio-Techne's Chief Operating Officer, expressed excitement for Dr. McManus' return and confidence in his ability to lead the Diagnostics and Genomics Segment through its next phase of growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
management
Rhea-AI Summary
Bio-Techne Corporation (TECH) to Showcase Cell and Gene Therapy Solutions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced that Kim Kelderman, current COO, and CEO effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference. The company is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, generating approximately $1.1 billion in net sales in fiscal 2023 with around 3,100 employees worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) files Drug Master File with FDA for ExCellerate™ GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
none
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) announced that Lunaphore and SIB Swiss Institute of Bioinformatics have been awarded Innosuisse funding for an innovation project. The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to accelerate the adoption of multiplex sequential immunofluorescence (seqIF™) technology in research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
AI
Bio-Techne Corp

Nasdaq:TECH

TECH Rankings

TECH Stock Data

7.60B
156.43M
1.05%
101.12%
3.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MINNEAPOLIS